Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $825.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by Citigroup from $740.00 to $825.00 in a research report released on Friday,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

REGN has been the subject of a number of other research reports. Truist Financial upped their price objective on shares of Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Robert W. Baird lifted their target price on shares of Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a “neutral” rating in a research report on Friday, July 31st. Royal Bank Of Canada increased their price objective on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the company a “sector perform” rating in a research note on Thursday, October 8th. Raymond James Financial increased their target price on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, UBS Group raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $660.00 to $978.00 in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $850.83.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $927.89 on Friday. The company has a current ratio of 4.06, a quick ratio of 3.66 and a debt-to-equity ratio of 0.08. The firm has a market cap of $95.54 billion, a price-to-earnings ratio of 20.49, a PEG ratio of 1.57 and a beta of 0.10. The stock’s 50-day moving average price is $793.30 and its two-hundred day moving average price is $738.05. Regeneron Pharmaceuticals has a 12-month low of $591.52 and a 12-month high of $935.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same period in the prior year, the business posted $11.83 EPS. The business’s revenue was up 36.3% on a year-over-year basis. On average, research analysts forecast that Regeneron Pharmaceuticals will post 49.10 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at approximately $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider directly owned 47,833 shares in the company, valued at $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in REGN. Western Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $26,000. Armstrong Advisory Group Inc. increased its holdings in Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 28 shares during the period. Activest Wealth Management raised its position in shares of Regeneron Pharmaceuticals by 780.0% in the 3rd quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 39 shares in the last quarter. Alpine Bank Wealth Management acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $34,000. Finally, Mowery & Schoenfeld Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $29,000. 83.31% of the stock is owned by institutional investors.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.